Full course of PD-1blockades

Phase 3Small molecule

Full course of PD-1blockades is one of 53 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaRecruiting

Nasopharyngeal CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

93 competitors in Nasopharyngeal Carcinoma

#DrugCompanyPhaseTrials

Tuoyi

CCoherus Oncology, Inc.

Phase 3

21 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

20 3

Beyfortus

BeiGene

Phase 3

6 4

Taxotere

AAvyxa

Phase 3

15 5

Tuoyi

SSun Yat-sen University

Phase 3

11 6

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

10 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

6 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

6 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 10

Induction Phase1

Genmab

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT07328841

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT07328854

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma2 trials

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Recruiting·MMing-Yuan Chen·Phase 3·NCT07328841·456 enrolled

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Recruiting·MMing-Yuan Chen·Phase 3·NCT07328854·346 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Full course of PD-1blockades. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Full course of PD-1blockades compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Full course of PD-1blockades. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ming-Yuan Chen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMing-Yuan Chen

Full course of PD-1blockades

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Nasopharyngeal Carcinoma2 trials

References

Drug Info

Quick Facts

Related News